antibody

APOB Monoclonal Antibody

MBS126148

0.1 mL

380 USD

monoclonal

mouse

nonconjugated

western blot, immunocytochemistry, flow cytometry, FACS

Antibody

APOB Monoclonal Antibody

APOB

FLDB; LDLCQ4

Apolipoprotein B-100; Apolipoprotein B-100; apolipoprotein B-100; apoB-48; apoB-100; apo B-100; mutant Apo B 100; apolipoprotein B48; apolipoprotein B (including Ag(x) antigen); apolipoprotein B

APOB

APOB; APOB; FLDB; LDLCQ4; Apo B-100; Apo B-48

APOB_HUMAN

Monoclonal

IgG

Mouse

Human

4563

Affinity Purification

1mg/ml

Store at -20 degree C (regular) or -80 degree C (long term). Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Western Blot (WB), Immunocytochemistry (ICC), Flow Cytometry (FC/FACS)

WB: 1:500 - 1:2000. ICC: 1:500 - 1:1000. FC: 1:50 - 1:200

Species: Human. Immunogen: Recombinant Protein

Immunogen: Recombinant protein of human APOB. Calculated Molecular Weight: 516kDa

Monoclonal

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels.

300669605

P04114.2

P04114

4563

Binding And Uptake Of Ligands By Scavenger Receptors Pathway (771599); Cell Surface Interactions At The Vascular Wall Pathway (106062); Chylomicron-mediated Lipid Transport Pathway (106157); Disease Pathway (530764); Diseases Associated With Visual Transduction Pathway (771581); FOXA1 Transcription Factor Network Pathway (137979); Fat Digestion And Absorption Pathway (194385); Fat Digestion And Absorption Pathway (194324); Hemostasis Pathway (106028); LDL-mediated Lipid Transport Pathway (106159)

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA- UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Jul 2008]

APOB: Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Defects in APOB are a cause of familial hypobetalipoproteinemia type 1 (FHBL1). A disorder characterized by highly reduced plasma concentrations of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia. Defects in APOB are a cause of familial ligand-defective apolipoprotein B-100 (FDB). FDB is a dominantly inherited disorder of lipoprotein metabolism leading to hypercholesterolemia and increased proneness to coronary artery disease (CAD). The plasma cholesterol levels are dramatically elevated due to impaired clearance of LDL particles by defective APOB/E receptors. Defects in APOB associated with defects in other genes (polygenic) can contribute to hypocholesterolemia. Protein type: Secreted; Carrier; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 2p24-p23. Cellular Component: Golgi apparatus; extracellular space; endoplasmic reticulum membrane; intracellular membrane-bound organelle; endoplasmic reticulum lumen; early endosome; extracellular region; cytosol; actin cytoskeleton; chylomicron; cell soma; cytoplasm; plasma membrane; endosome membrane. Molecular Function: heparin binding; protein binding; low-density lipoprotein receptor binding; cholesterol transporter activity; phospholipid binding. Biological Process: phototransduction, visible light; lipoprotein catabolic process; response to lipopolysaccharide; response to carbohydrate stimulus; post-embryonic development; response to selenium ion; triacylglycerol catabolic process; retinoid metabolic process; transmembrane transport; receptor-mediated endocytosis; nervous system development; cholesterol metabolic process; cholesterol transport; in utero embryonic development; response to virus; regulation of cholesterol biosynthetic process; lipoprotein metabolic process; cholesterol efflux; sperm motility; cholesterol homeostasis; fertilization; lipoprotein transport; lipoprotein biosynthetic process; artery morphogenesis; spermatogenesis; triacylglycerol mobilization; blood coagulation; leukocyte migration. Disease: Hypercholesterolemia, Autosomal Dominant, Type B; Hypobetalipoproteinemia, Familial, 1

0.1 mL

380 USD

0.2 mL

555